NLS PHARMACEUTICS LTD's ticker is NLSP and the CUSIP is H57830103. A total of 6 filers reported holding NLS PHARMACEUTICS LTD in Q1 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $3,747 | -70.5% | 3,406 | -65.4% | 0.00% | – |
| Q4 2022 | $12,694 | +41.0% | 9,840 | -35.5% | 0.00% | – |
| Q2 2022 | $9,000 | -40.0% | 15,252 | +44.1% | 0.00% | – |
| Q1 2022 | $15,000 | +7.1% | 10,582 | -17.1% | 0.00% | – |
| Q4 2021 | $14,000 | -91.0% | 12,772 | -79.6% | 0.00% | – |
| Q3 2021 | $156,000 | +2500.0% | 62,473 | +3145.4% | 0.00% | – |
| Q2 2021 | $6,000 | – | 1,925 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Renaissance Technologies | 21,700 | $31,000 | 0.00% |
| UBS Group AG | 10,582 | $15,000 | 0.00% |
| CONCOURSE FINANCIAL GROUP SECURITIES, INC. | 0 | $0 | 0.00% |
| GEODE CAPITAL MANAGEMENT, LLC | 14,362 | $20,000 | 0.00% |
| Citadel Advisors | 21,632 | $31,000 | 0.00% |
| Tower Research Capital LLC (TRC) | 3,665 | $5,000 | 0.00% |